Propanc Biopharma Inc’s Lock-Up Period To Expire on February 11th (OTCMKTS:PPCB)

Posted by Jessica Moore on Feb 8th, 2026

Propanc Biopharma’s (OTCMKTS:PPCB – Get Free Report) lock-up period is set to expire on Wednesday, February 11th. Propanc Biopharma had issued 1,000,000 shares in its public offering on August 15th. The total size of the offering was $4,000,000 based on an initial share price of $4.00. After the end of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Propanc Biopharma Trading Down 6.0%

Shares of PPCB stock opened at $0.19 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.24 and a current ratio of 2.24. The firm has a market capitalization of $2.86 million, a PE ratio of 0.00 and a beta of 3.66. The stock has a fifty day simple moving average of $0.53 and a two-hundred day simple moving average of $2.07. Propanc Biopharma has a 52-week low of $0.16 and a 52-week high of $11.00.

Institutional Investors Weigh In On Propanc Biopharma

An institutional investor recently bought a new position in Propanc Biopharma stock. Virtu Financial LLC bought a new position in Propanc Biopharma Inc (OTCMKTS:PPCB – Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned about 0.33% of Propanc Biopharma at the end of the most recent reporting period.

Propanc Biopharma Company Profile

(Get Free Report)

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.